Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03293888 · ClinicalTrials.gov registry record
Spectral Analysis Probe to Identify Glioblastoma Cells
A clinical trial, sponsored by University of Oklahoma.
- Terminated
- Registry status
- 12
- Enrollment target
NCT03293888: Clinical Trial study, sponsored by University of Oklahoma.
NCT03293888 is a clinical trial that was terminated before completion, run by University of Oklahoma. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03293888 was terminated before completion, sponsored by University of Oklahoma.
- TERMINATED
- Registry status
- 12 participants
- Enrollment target
Study Summary
This is a pilot, observational study to evaluate the intraoperative sensitivity of the Chaos Wand in detecting tumor tissue with glioblastoma disease.
Primary Outcome
For participants newly diagnosed with glioblastoma multiforme or patients who are suspected of having glioblastoma on pre-operative imaging who consent to the use of the Chaos Wand during surgery, 15-20 spectral readings will be compared to histopathology as ground truth to measure the sensitivity of the Chaos Wand to detect glioblastoma. For example, if a patient has 15 spectral readings but only 13 are histologically consistent with cancer, then the sensitivity of the wand would be 13/15\*100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-10-31 |
| Est. Completion | 2018-09-30 |
Why NCT03293888 stopped before completion
NCT03293888 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03293888 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03293888 about?
NCT03293888 is a clinical study titled "Spectral Analysis Probe to Identify Glioblastoma Cells". This is a pilot, observational study to evaluate the intraoperative sensitivity of the Chaos Wand in detecting tumor tissue with glioblastoma disease.
What is the current status of trial NCT03293888?
This trial is currently terminated. The enrollment target is 12 participants. The study started on 2017-10-31. Estimated completion is 2018-09-30.
Who is sponsoring clinical trial NCT03293888?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI